Diphtheria
Corynebacterium diphtheriae
stain of diphtheria
CDC describes diphtheria as "an upper respiratory tract illness characterized by sore throat, low-grade fever, and an adherent membrane of the tonsil(s), pharynx, and/or nose". Diphtheria is a rapidly developing, acute, febrile infection which involves both local and systemic pathology. A local lesion develops in the upper respiratory tract and involves necrotic injury to epithelial cells. As a result of this injury, blood plasma leaks into the area and a fibrin network forms which is interlaced with with rapidly-growing C. diphtheriae cells.
Author: Chu
DoD Instruction 6025.19
12 Oct 05

Sample Q&A: Diphtheria- The Vaccine

Is there a treatment for diphtheria?
Diphtheria is treated with both antibiotics and with diphtheria antitoxin. Antitoxin is the name for antibodies that neutralize toxins. Diphtheria antitoxin is produced in horses and was first used in the United States in 1891. Antitoxin is not effective against toxin that is already attached to the body's tissues, but antitoxin will neutralize circulating poison and prevent the disease from getting worse. The patient should be tested for antitoxin sensitivity (because it is horse-derived) before administration.
Recommendations of the Advisory Committee on Immunization Practices (ACIP) and Recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for Use of Tdap Among Health-Care Personnel
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Information Paper
Package Insert - Vaccine
Package Insert - Vaccine
Package Insert - Vaccine
Package Insert - Vaccine
Package Insert - Vaccine
Package Insert - Vaccine
Package Insert - Vaccine
GlaxoSmithKline 01 Mar 12
Boostrix
GlaxoSmithKline 14 Apr 09
Pentacel
GlaxoSmithKline 26 Jun 08
Kinrix
MMQC-11-1074 02 Feb 11
UPDATED RECOMMENDATIONS FOR USE OF TETANUS TOXOID, REDUCED DIPHTHERIA TOXOID AND ACELLULAR PERTUSSIS (TDAP) VACCINE FROM THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES, 2010
VIS